Montelukast Ametas

Montelukast, the active ingredient in Montelukast Ametas, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. By blocking cysteinyl leukotriene receptors, it helps reduce airway inflammation and constriction in patients with asthma, allergic rhinitis, and exercise‑induced bronchoconstriction.

GNH USA supplies Montelukast Ametas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, with consistent quality standards.

Montelukast is a leukotriene receptor antagonist used to treat conditions driven by leukotriene‑mediated inflammation.

Asthma: improves control of persistent asthma and reduces frequency of exacerbations. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Abdominal pain: occasional stomach discomfort. - Cough: transient dry cough.

Serious or Rare Side Effects: - Allergic reactions: rash, hives, swelling of face or throat. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Liver enzyme elevation: abnormal liver function tests.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Assess asthma control: confirm that patient’s asthma is not uncontrolled before initiating therapy. - Monitor for neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Evaluate liver function: consider baseline liver enzymes in patients with hepatic disease. - Use with caution in the elderly: adjust monitoring due to potential comorbidities. - Pregnancy and lactation: discuss potential risks with the prescriber as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma concentrations of Montelukast. - Rifampin: can significantly lower Montelukast exposure.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): may increase risk of neuropsychiatric side effects. - Antihistamines: additive effect on allergic symptom control. - Warfarin: monitor INR as Montelukast may affect anticoagulation.